Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug ...
13h
Zacks Small Cap Research on MSNQNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26QNRX READ THE FULL QNRX RESEARCH REPORT Progressing studies of QRX003; positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage, specialty pharmaceutical company that ...
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...
1d
inews.co.uk on MSNThe 3.5m people with rare diseases who face worsening treatment and diagnosis ratesRare diseases affect one in 17 people in the UK, but a Government initiative designed to improve their quality of life will ...
Genetically targeted technologies are built on Nobel Prize-winning science. They represent a scientific “quantum leap” that ...
Rare diseases - a medical condition so obscure that even your doctor has to Google. Despite their name, these diseases ...
Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...
KRRO-110 is the first RNA editing development candidate from Korro's proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results